Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Three IVF attempts increase chances of a live birth

Just one in three women gives birth after a single IVF attempt, but the cumulative chance of a live birth increases with each cycle - where women are offered three cycles nearly two thirds go on to have babies, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in Sweden.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Total Nutraceutical Solutions, Inc. (TNS), announced that it has filed a Provisional Use Patent application on the ability of a proprietary natural organic mushroom formula to control oxidative stress.

9 Nov 2009

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Rituximab drug potentially effective for treating Graves' eye disease, shows study

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.

7 Nov 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

6 Nov 2009

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.

6 Nov 2009

Bodhi Body selects public relations firm and marketing agency Zion & Zion

Bodhi Body is a new way to look at healthcare. Through the incorporation of integrated medical and wellness services ranging from IV therapy to yoga and naturopathic medicine, Bodhi Body improves quality of life. In an effort to launch the brand and facility with maximum impact and to rapidly recruit clients, the company has engaged top Phoenix public relations firm and marketing agency Zion & Zion.

6 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Aging population need to be included in information technology, suggest psychologists

Technology is no longer what it used to be: Computers have replaced typewriters and landlines are in rapid decline. Technological advances are being made every day, making many of our lives easier and allowing information to be more accessible and available. However for some people, such as the aging population, technological progress can in fact be more limiting.

5 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

Osiris Therapeutics reports financial results for the third quarter of 2009

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its financial results for the third quarter of 2009.

4 Nov 2009

TNF-alpha inhibitors ranked top for reducing biologics spend

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilars of tumor necrosis factor (TNF)-alpha inhibitors stand to erode $9.6 billion in brand sales (Amgen's Enbrel, Abbott's Humira and Centocor Ortho Biotech/Schering-Plough's Remicade) in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018. This use of TNF-alpha biosimilars will save healthcare systems in the U.S. and Europe $4 billion.

4 Nov 2009

Study on asbestos-related diseases in Libby launched

Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List."

4 Nov 2009

International Omega-3 Awareness Day to educate public about proven health benefits of omega-3

Scientific evidence of the health benefits of omega-3's are now so firmly established that omega-3 expert Carol A. Locke, MD, with a team of world-renowned doctors, has spearheaded the first ever International Omega-3 Awareness Day on March 3rd, 2010. Learn more at www.Omega3Day.com.

4 Nov 2009

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Thanks to a two year, $974,024 NIH-funded ARRA (American Recovery and Reinvestment Act) grant, Saint Louis University and Southern Illinois University Edwardsville researchers are working to find better ways to manage chronic pain by treating neuroinflammation.

4 Nov 2009

Takeda Pharmaceuticals strengthens its North American market

Takeda Pharmaceuticals North America, Inc., today announced the incorporation of Takeda Pharmaceuticals Mexico, S.A. de C.V. This expansion strengthens the company's North American presence, bolstering existing operations in the United States and Canada. Takeda Pharmaceuticals Mexico will be headquartered in Mexico City.

4 Nov 2009

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010.

4 Nov 2009

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

A new study published in Nutrition Journal indicates that XanGo- Juice, a market-leading, premium mangosteen beverage, has lowered levels of C-reactive protein (CRP) in overweight and obese people in a randomized, double-blind, placebo-controlled human trial.

4 Nov 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Three IVF attempts increase chances of a live birth

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

TNS files Provisional Use Patent application on the ability of a natural organic mushroom formula

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Rituximab drug potentially effective for treating Graves' eye disease, shows study

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Bodhi Body selects public relations firm and marketing agency Zion & Zion

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Aging population need to be included in information technology, suggest psychologists

Bursting common myths about psoriasis

Osiris Therapeutics reports financial results for the third quarter of 2009

TNF-alpha inhibitors ranked top for reducing biologics spend

Study on asbestos-related diseases in Libby launched

International Omega-3 Awareness Day to educate public about proven health benefits of omega-3

Researchers to find better ways to manage chronic pain by treating neuroinflammation

Takeda Pharmaceuticals strengthens its North American market

Survey shows majority of rheumatologists would prescribe Actemra drug for rheumatoid arthritis

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in